HOLON, Israel, Aug. 29,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that management will present virtually at the
H.C. Wainwright 26th Annual Global Investment Conference. The
presentation will be available on demand on the Investor Relations
section of Compugen's website at www.cgen.com from
Monday, September 9, 2024, 7:00 AM
ET for 30 days.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has two proprietary product
candidates in Phase 1 development: COM701, a potential
first-in-class anti-PVRIG antibody and COM902, a potential
best-in-class antibody targeting TIGIT for the treatment of solid
tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the
TIGIT component is derived from Compugen's clinical stage
anti-TIGIT antibody, COM902, is in Phase 3 development by
AstraZeneca through a license agreement for the development of
bispecific and multispecific antibodies. In addition, the
Company's therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms
of immune resistance, of which the most advanced program, COM503, a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which has been granted IND clearance from the FDA, is
licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302233882.html
SOURCE Compugen Ltd.